Magazine Article | February 1, 2021

How Small Patient Advocacy Groups Can Help Advance Drug Development

Source: Life Science Leader

By Sue Washer

Engagement with patient advocacy groups is now a common component of drug development and communications strategies. Many biopharmaceutical companies are actively engaged with large disease society organizations such as the American Heart Association, American Diabetes Association, and the American Cancer Society, funding workshops, training grants, and research. Large patient advocacy and disease organizations are attractive to biopharmaceutical companies because they have broad reach and well-developed infrastructures to support multiple educational and research opportunities. Working with these organizations can streamline industry efforts to engage with specific patient groups, which can be especially beneficial when developing therapies in larger indications.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader